Spero Therapeutics (SPRO)
(Real Time Quote from BATS)
$1.48 USD
+0.05 (3.50%)
Updated Apr 26, 2024 01:34 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Balance Sheet
Fiscal Year End for Spero Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 76 | 109 | 146 | 127 | 82 |
Receivables | 51 | 1 | 3 | 6 | 9 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 3 | 9 | 6 | 5 |
Total Current Assets | 131 | 114 | 158 | 139 | 95 |
Net Property & Equipment | 0 | 0 | 1 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 47 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 6 | 6 | 5 | 4 |
Total Assets | 182 | 125 | 171 | 153 | 106 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 1 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 9 | 14 | 12 | 22 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 27 | 10 | 2 | 0 | 0 |
Total Current Liabilities | 37 | 22 | 19 | 14 | 27 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 34 | 22 | 9 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 49 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 76 | 49 | 83 | 21 | 32 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 498 | 490 | 456 | 410 | 274 |
Retained Earnings | -391 | -414 | -367 | -278 | -199 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 107 | 76 | 88 | 132 | 75 |
Total Liabilities & Shareholder's Equity | 182 | 125 | 171 | 153 | 106 |
Total Common Equity | 107 | 76 | 88 | 132 | 75 |
Shares Outstanding | 53.00 | 52.40 | 32.30 | 27.10 | 19.10 |
Book Value Per Share | 2.02 | 1.45 | 2.73 | 4.87 | 3.90 |
Fiscal Year End for Spero Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 76 | 94 | 78 | 96 |
Receivables | NA | 51 | 3 | 2 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 4 | 5 | 9 | 4 |
Total Current Assets | NA | 131 | 102 | 88 | 102 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 47 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 6 | 6 |
Total Assets | NA | 182 | 107 | 99 | 113 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 7 | 7 | 6 | 9 |
Income Taxes Payable | NA | 0 | 2 | 0 | 0 |
Other Current Liabilities | NA | 27 | 14 | 9 | 12 |
Total Current Liabilities | NA | 37 | 25 | 17 | 23 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 34 | 24 | 22 | 20 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 76 | 53 | 44 | 48 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 498 | 496 | 494 | 492 |
Retained Earnings | NA | -391 | -442 | -439 | -427 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 107 | 54 | 55 | 65 |
Total Liabilities & Shareholder's Equity | NA | 182 | 107 | 99 | 113 |
Total Common Equity | 0 | 107 | 54 | 55 | 65 |
Shares Outstanding | 53.80 | 53.00 | 52.70 | 52.50 | 52.50 |
Book Value Per Share | 0.00 | 2.02 | 1.02 | 1.04 | 1.24 |